DK1419240T3 - Fremstilling og anvendelse af humane CD124- og CD116-positive tumorcellelinier til fremstilling af allogene eller semi-allogene immumterapeutika - Google Patents
Fremstilling og anvendelse af humane CD124- og CD116-positive tumorcellelinier til fremstilling af allogene eller semi-allogene immumterapeutikaInfo
- Publication number
- DK1419240T3 DK1419240T3 DK02758474.7T DK02758474T DK1419240T3 DK 1419240 T3 DK1419240 T3 DK 1419240T3 DK 02758474 T DK02758474 T DK 02758474T DK 1419240 T3 DK1419240 T3 DK 1419240T3
- Authority
- DK
- Denmark
- Prior art keywords
- preparation
- allogeneic
- cell lines
- immunotherapy
- semi
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 230000000735 allogeneic effect Effects 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000000507 anthelmentic effect Effects 0.000 abstract 1
- 230000000567 anti-anemic effect Effects 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000002141 anti-parasite Effects 0.000 abstract 1
- 230000003356 anti-rheumatic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000003096 antiparasitic agent Substances 0.000 abstract 1
- 239000003435 antirheumatic agent Substances 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000855 fungicidal effect Effects 0.000 abstract 1
- 239000000417 fungicide Substances 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002423 protozoacide Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001646 thyrotropic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000012873 virucide Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/46482—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10139428A DE10139428A1 (de) | 2001-08-17 | 2001-08-17 | Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika |
PCT/EP2002/009260 WO2003023023A1 (de) | 2001-08-17 | 2002-08-19 | Herstellung und verwendung von humanen cd124 und cd116 positiven tumorzelllinien zur herstellung von allogenen oder semi-allogenen immuntherapeutika |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1419240T3 true DK1419240T3 (da) | 2011-10-17 |
DK1419240T4 DK1419240T4 (da) | 2018-10-29 |
Family
ID=7695095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02758474.7T DK1419240T4 (da) | 2001-08-17 | 2002-08-19 | : Fremstilling og anvendelse af humane CD124- og CD116-positive tumorcellelinier til fremstilling af allogene eller semi-allogene |
Country Status (8)
Country | Link |
---|---|
US (2) | US8455253B2 (da) |
EP (2) | EP2361973A3 (da) |
AT (1) | ATE513900T1 (da) |
CA (1) | CA2457287C (da) |
DE (1) | DE10139428A1 (da) |
DK (1) | DK1419240T4 (da) |
ES (1) | ES2371021T5 (da) |
WO (1) | WO2003023023A1 (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10139428A1 (de) | 2001-08-17 | 2003-03-27 | Nemod Immuntherapie Ag | Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika |
AU2003260426A1 (en) | 2002-08-16 | 2004-03-11 | Glycotope Gmbh | Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds |
EP1654353B1 (en) | 2003-08-18 | 2013-05-22 | Glycotope GmbH | Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof |
ES2620261T3 (es) | 2006-09-10 | 2017-06-28 | Glycotope Gmbh | Uso de células humanas de origen leucémico mieloide para expresión de anticuerpos |
PL1920781T3 (pl) * | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
FR2931163B1 (fr) * | 2008-05-16 | 2013-01-18 | Ets Francais Du Sang | Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive |
CN103814123A (zh) | 2011-08-22 | 2014-05-21 | 葛莱高托普有限公司 | 携带肿瘤抗原的微生物 |
NL2009102C2 (en) * | 2012-07-02 | 2014-01-06 | Dcprime B V | Method for dc-loading. |
EP2743344A1 (en) * | 2012-12-11 | 2014-06-18 | DCPrime B.V. | Therapeutic cancer vaccines derived from a novel dendritic cell line |
WO2018096078A1 (en) | 2016-11-25 | 2018-05-31 | Glycotope Gmbh | Serum-free cultivation of progenitor dendritic cells |
US20190076473A1 (en) * | 2017-09-14 | 2019-03-14 | Cellular Approaches, Inc. | Autologous and allogenic macrophages and monocytes for use in therapeutic methods |
DK3794042T3 (da) | 2018-05-18 | 2024-04-15 | Daiichi Sankyo Co Ltd | Anti-muc1-exatecet-antistof-lægemiddelkonjugat |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6300090B1 (en) * | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
US5648219A (en) * | 1995-06-07 | 1997-07-15 | Zymogenetics, Inc. | Immortalized dendritic cells |
AU2326297A (en) * | 1996-03-06 | 1997-09-22 | I. Belloch Corporation | Method for treating liquid materials |
US5811297A (en) * | 1996-03-07 | 1998-09-22 | Amba Biosciences, Llc | Immortalized hematopoietic cell lines, cell system thereof with stromal cells, in vitro, ex vivo and in vivo uses, & in vitro generation of dendritic cells and macrophages |
JP2002501377A (ja) * | 1997-04-15 | 2002-01-15 | ダナ−ファーバー キャンサー インスティテュート インク. | 樹状細胞ハイブリッド |
US20020041868A1 (en) * | 1997-04-15 | 2002-04-11 | Charles Nicolette | Cell fusions and methods of making and using the same |
US20020090381A1 (en) * | 1999-04-09 | 2002-07-11 | H. Kim Bottomly | System for controlling immune system response to antigen |
DE10019075B4 (de) * | 2000-04-18 | 2007-01-18 | Vision 7 Gmbh | Verwendung von CD34 oder einem davon abgeleiteten Polypeptid als Zell-Oberflächen- bzw. Gentransfer-Marker |
DE10139428A1 (de) | 2001-08-17 | 2003-03-27 | Nemod Immuntherapie Ag | Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika |
-
2001
- 2001-08-17 DE DE10139428A patent/DE10139428A1/de not_active Ceased
-
2002
- 2002-08-19 EP EP10185184A patent/EP2361973A3/de not_active Ceased
- 2002-08-19 AT AT02758474T patent/ATE513900T1/de active
- 2002-08-19 WO PCT/EP2002/009260 patent/WO2003023023A1/de not_active Application Discontinuation
- 2002-08-19 CA CA2457287A patent/CA2457287C/en not_active Expired - Lifetime
- 2002-08-19 ES ES02758474.7T patent/ES2371021T5/es not_active Expired - Lifetime
- 2002-08-19 EP EP02758474.7A patent/EP1419240B2/de not_active Expired - Lifetime
- 2002-08-19 US US10/486,966 patent/US8455253B2/en not_active Expired - Lifetime
- 2002-08-19 DK DK02758474.7T patent/DK1419240T4/da active
-
2012
- 2012-07-19 US US13/553,157 patent/US9029143B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2457287A1 (en) | 2003-03-20 |
EP2361973A3 (de) | 2012-08-15 |
DE10139428A1 (de) | 2003-03-27 |
EP1419240B1 (de) | 2011-06-22 |
EP1419240A1 (de) | 2004-05-19 |
WO2003023023A1 (de) | 2003-03-20 |
CA2457287C (en) | 2016-01-19 |
US8455253B2 (en) | 2013-06-04 |
DK1419240T4 (da) | 2018-10-29 |
ATE513900T1 (de) | 2011-07-15 |
US20040265998A1 (en) | 2004-12-30 |
EP1419240B2 (de) | 2018-07-11 |
WO2003023023B1 (de) | 2003-11-27 |
ES2371021T3 (es) | 2011-12-26 |
US9029143B2 (en) | 2015-05-12 |
US20120308607A1 (en) | 2012-12-06 |
ES2371021T5 (es) | 2018-11-20 |
EP2361973A2 (de) | 2011-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1419240T3 (da) | Fremstilling og anvendelse af humane CD124- og CD116-positive tumorcellelinier til fremstilling af allogene eller semi-allogene immumterapeutika | |
ATE390926T1 (de) | Immunstimulation durch chemisch modifizierte rna | |
DK1165791T3 (da) | Humant cytokin som zalpha-receptor-ligand og anvendelse deraf | |
DK1019082T3 (da) | Fremgangsmåde til moduleringen af neovaskularisering og/eller væksten af kollaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser | |
ATE286118T1 (de) | Anwendungen für humane nicht autologe, mesenchymale stammzellen | |
DK1028737T3 (da) | Humane mesenchymale stamceller fra perifert blod | |
BR0210599A (pt) | Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril | |
DE69032484T2 (de) | Zusammensetzungen und deren verwendung zur förderung der immunopotentiation | |
NO911689D0 (no) | Neurotrofisk faktor fra hjerne. | |
HK1044484A1 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide. | |
YU102203A (sh) | Vakcinacija sa jednokratnom dozom mycoplasma hyopneumoniae | |
NO20010922D0 (no) | FremgangsmÕte for DNA vaksinering | |
TW200513280A (en) | Microprojection array immunization patch and method | |
BR0210839A (pt) | Sistema de recombinação, método para remover uma sequência de dna do dna cromossÈmico de uma célula ou organismo eucarióticos, organismo, cultura de célula, órgão, tecido, parte ou material de propagação transgênico, e, uso de um organismo ou de uma cultura de célula, órgão, tecido, parte ou material de propagação transgênico | |
DK1699915T3 (da) | Anvendelse af erythropoietin til levervævsregenerering | |
ES2084045T3 (es) | Bacterias que albergan vectores de expresion que codifican el factor neurotrofico ciliar humano (h-cntf), su uso en la produccion de h-cntf, anticuerpos para h-cntf y el uso de h-cntf en el tratamiento medico. | |
MX9708854A (es) | Terapia de genes para regulacion de celulas efectoras. | |
AR004341A1 (es) | Vacunas contra tumores y procedimiento para su produccion. | |
FR2805821B1 (fr) | Sequences d'acides amines facilitant la penetration d'une substance d'interet a l'interieur des cellules et/ou des noyaux cellulaires | |
AU8180001A (en) | Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells | |
Sinclair | Cysteamine: Differential X-ray protective effect on Chinese hamster cells during the cell cycle | |
FI893681A0 (fi) | N-2,3-butadienyltri- och tetra-aminoalkanderivat. | |
DK1509244T3 (da) | Ny fremgangsmåde og præparat til at producere en cellulær allogen vaccine | |
CY1106396T1 (el) | Γραμμικες ή κυκλικες ουριες, μεθοδος παρασκευης αυτων και φαρμακευτικες συνθεσεις οι οποιες τις πepιεχουν | |
BRPI0410655A (pt) | composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação |